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Purpose or Objective: Image-guided intensity modulated 
radiotherapy (IG-IMRT) reduces dose to organs at risk (OARs) 
compared to 3D-conformal radiotherapy (3D-CRT). Currently 
it is not known to what extent this reduces late toxicity in 
prostate cancer patients. We previously reported on 
significant reductions in dose to OARs and acute toxicity. The 
aim of this study was to assess the therapeutic gain with IG-
IMRT in terms of long-term toxicity reductions, and to 
establish to what extent acute toxicity was associated with 
late side effects. For that purpose we used prospective data 
of two randomized trials. 
 
Material and Methods: A total of 242 IG-IMRT patients from a 
hypofractionation trial (2007-2010) and 189 3D-CRT patients 
from a dose escalation trial (1997-2003) with ≥2 completed 
questionnaires were selected. All patients received 78 Gy in 2 
Gy fractions. Applied margins were 10 mm for 3D-CRT and 5-8 
mm for IG-IMRT, all with 0 mm margin towards the rectum 
for the 10 Gy boost. The mean dose to the anorectum was 
34.4 Gy vs. 47.3 Gy, 23.6 Gy vs. 44.6 Gy for the anal canal 
and 33.1 Gy vs. 43.2 Gy for the bladder (all significantly 
reduced with IG-IMRT). Late toxicity was scored using 
identical questionnaires and case report forms according to 
RTOG/EORTC scoring criteria. Study endpoints were grade ≥2 
(G≥2) gastrointestinal (GI) and genitourinary (GU) toxicity. 
Cumulative incidences of G≥2 endpoints were calculated. Cox 
regression was used to determine Relative Risks (RR) for IG-
IMRT, adjusted for baseline factors. RRs of acute toxicity as a 
predictor for late G≥2 endpoints were also calculated. 
 
Results: Median follow-up was 60 months. The five-year (5y) 
cumulative incidence of late G≥2 GI toxicity was 25.4% for IG-
IMRT compared to 36.4% for 3D-CRT (RR=0.62, p=0.009) 
(Figure 1). This resulted from significantly lower incidences 
of increased stool frequency ≥6/day (4.3% vs 16.5%, RR=0.24, 
p<0.001) and non-significant lower incidences of G≥2
(needing medical intervention) rectal bleeding (RR=0.67, 
p=0.4), rectal pain/cramps (RR=0.59, p=0.13), and proctitis 
(RR=0.38, p=0.05). G≥2 anal incontinence (with use of pads) 
was not reduced (RR=1.02, p=0.9). With regard to GU 
toxicity, a non-significant increase was observed with IG-
IMRT with 5y incidences of 46.9% vs. 37.1% for 3D-CRT 
(RR=1.3, p=0.12). Acute toxicity levels G≥2 (mainly proctitis) 
were 29% vs. 51% (p<0.01). Acute GI G≥2 toxicity was 
predictive for late G≥2 toxicity (RR=2.9 for IG -IMRT, 2.5 for 
3D-CRT, both p<0.01), especially for rectal discomfort 
(RR=7.2, p<0.001) in IG-IMRT, and rectal incontinence 
(RR≈3.5, p<0.01) in both groups. IG-IMRT patients with acute 
GU G≥2 complaints had a 1.81 fold (p=0.002) increased risk of 
late GU G≥2 toxicity, compared to 2.37 (p=0.001) for 3D-CRT. 
 
 
 
Conclusion: IG-IMRT for prostate cancer was beneficial since 
it significantly reduced the incidence of long-term GI 
toxicity, as a result of lower doses to OARs and reduced 
acute toxicity levels. GU toxicity was not reduced despite 
significant reductions in bladder dose.  
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Purpose or Objective: To assess outcome and toxicity of 
stereotactic body radiotherapy (SBRT) in prostate cancer 
patients (pts) with recurrent isolated lymph node metastases 
(LNM). 
 
Material and Methods: Between September 2008 and 
December 2014, 40 prostate cancer pts with 47 recurrent 
isolated LNM, were treated with SBRT. Median age was 74 yrs 
(range, 58-83), median Gleason score at the primary 
diagnosis was 7 (range, 5-10). Median and mean time from 
primary treatment to SBRT were 37.45 and 62.6 m, 
respectively (range 11.16–216.03). Diagnosis was performed 
with choline (ch) PET/CT, and the mean and median PSA 
values before SBRT were 5.6 and 4.2 ng/ml, respectively. Six 
(15%) pts were treated in different sessions for metachronous 
metastases, and one (2%) underwent SBRT for two 
synchronous metastases. 21 (52.5%) pts underwent only SBRT, 
remaining 19 (47.5%) received also androgen deprivation 
therapy (ADT). Gross tumor volume (GTV) was delineated 
using choline uptake and planning target volume (PTV) was 
defined as the GTV plus a 5-8 mm isotropic margin. Mean and 
median volume of GTV and PTV were 6.63 cc and 3 cc and 
25.03 and 15.03 cc, respectively. In 90% of cases 5 fractions 
of 6-8 Gy were delivered. Response was assessed with PSA 
evaluation scheduled every 3 m during the first year and then 
every 6 m. Pts with a reduction or a stability of PSA level 
were considered responders. Being evaluation of response 
with ch-PET-CT not mandatory, it was done in 23 (57.5%) pts. 
 
Results: Mean and median follow-up were 30.18 and 23.8 m, 
respectively (range 3.73-79.8). Mean time of biochemical 
progression from the end of SBRT was 15.54 m (range 1.16 - 
48.86), and the 2-years biochemical progression free survival 
(b-PFS) was 44%. We registered a complete concordance 
between PSA increase and progression of disease shown at 
ch-PET/CT. Sixteen (40%) of the pts experienced no disease 
recurrence after SBRT. Of 21 no-ADT pts, 16 (76%) were still 
free from ADT (mean 26.18 m), whereas remaining 5 (24%) 
had a mean deferment time of ADT of 13.58 m. At univariate 
analysis, Gleason score >7 is related with a worse b-PFS 
(p=0.02). Acute grade 2 diarrhea was registered in 1 (2,5%) 
case. Grade 3 small bowel late toxicity was observed in only 
one (2.5%) case 11.76 m after the end of SBRT. 
 
Conclusion: SBRT resulted effective and generally well 
tolerated by pts. PSA level is a valid tool for response 
evaluation and ch-PET/CT can be useful for pts with 
documented biochemical progression. 
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Purpose or Objective: Subtle changes in serum testosterone 
have been noted in prostate cancer patients, without 
androgen blockade, treated with radiotherapy as well as 
radical prostatectomy (RP). The significance of these changes 
